NeuroThera Labs Filed Patents for Psychedelic Therapies
The company published three patent applications for psychedelic compounds combined with PEA technology.
Updated on Sept. 23, 2026 in Substance Abuse
Live Poll
Do you trust that combining psychedelic compounds with other drugs will create safer mental health treatments?
NeuroThera Labs has officially published three U.S. patent applications involving the combination of PEA technology with LSD, ketamine, and ibogaine. These filings aim to support the development of novel therapeutic treatments for conditions including depression, PTSD, and substance use disorders.
Why it matters
The move represents a significant expansion of the company's intellectual property portfolio. These combinations are intended to create new, targeted therapeutic approaches for managing various neuropsychiatric conditions and chronic pain.
NeuroThera Labs filed three new U.S. patent applications for combinations of psychedelic compounds with N-acylethanolamines. This expands upon a prior patent filing that focused on MDMA and N-acylethanolamine combinations.
The players
NeuroThera Labs
NeuroThera Labs is a pharmaceutical company that specializes in the development of innovative treatments for neuropsychiatric conditions and chronic pain.
Clearmind Medicine
Clearmind Medicine is a biotech company focused on discovering and developing novel therapeutics for under-treated mental health and addiction disorders.
The details
The intellectual property expansion is facilitated by an ongoing collaboration between NeuroThera Labs and Clearmind Medicine. The filings specifically target the integration of PEA technology with potent compounds to address complex mental health and pain-related disorders.
Timeline
April 29, 2026: SciSparc filed an Annual Report on Form 20-F.
September 23, 2026: Three U.S. patent applications were published.
The Big Picture
These patent filings reflect a structural effort to formalize intellectual property within the emerging psychedelic medicine sector. This development aligns with the regulatory framework set by the FDA's 2023 draft guidance on clinical trials for psychedelic drugs as companies race to commercialize new therapeutic standards.
These filings represent the early stage of research and will not impact current treatment options or healthcare access. Patients should consult with medical professionals regarding existing approved therapies for depression or PTSD rather than pending research developments.
The takeaway
The publication of these patents highlights the growing corporate focus on stabilizing psychedelic compounds for therapeutic use. As research continues, the integration of PEA technology with these substances remains a key area of study for the treatment of complex neuropsychiatric conditions.
Further reading
Learn more about the latest research and regulatory shifts in Substance Abuse across the country.
Live Poll
Do you trust that combining psychedelic compounds with other drugs will create safer mental health treatments?
